Featured Research

from universities, journals, and other organizations

How the immune system responds to hepatitis A virus

Date:
June 21, 2011
Source:
Southwest Foundation for Biomedical Research
Summary:
A surprising finding in a study comparing hepatitis C virus (HCV) with hepatitis A virus (HAV) infections in chimpanzees sheds new light on the nature of the body's immune response to these viruses.

A surprising finding in a study comparing hepatitis C virus (HCV) with hepatitis A virus (HAV) infections in chimpanzees by a team that includes scientists from the Texas Biomedical Research Institute sheds new light on the nature of the body's immune response to these viruses.

Related Articles


Understanding how hepatitis C becomes chronic is very important because some 200 million people worldwide and 3.2 million people in the U.S. are chronically infected with HCV and are at risk for progression to cirrhosis and liver cancer. Hepatitis C associated liver disease is the most common indication for liver transplantation, while liver cancer due to HCV infection is now the most rapidly increasing cause of cancer death in the U.S.

"Remarkably, we found that HAV was more adept at evading the innate immune response than HCV, the virus that ultimately causes chronic infections," said Robert E. Lanford, Ph.D., a Texas Biomed virologist. The novel findings demonstrate that HAV is the stealthier virus when it comes to evading the innate immune response, despite the lack of persistent infections.

Hepatitis C infections are characterized by a failure of the immune system to combat and eliminate the virus. "We suspect this failure of the immune system shares attributes with other persistent viruses such as HIV and hepatitis B virus," said Lanford. By comparing two similar viruses that infect the liver, one that is always cleared by the immune system, HAV, and one that frequently evades the immune response, HCV, the team hoped to unravel the mystery of how HCV causes lifelong persistent infections.

The research team involved scientists from Texas Biomed in San Antonio, the University of North Carolina (UNC) at Chapel Hill, and Nationwide Children's Hospital in Columbus, Ohio. The study performed in chimpanzees at Texas Biomed's Southwest National Primate Research Center (SNPRC) and funded by the National Institutes of Health, is published June 20 in Proceedings of the National Academy of Sciences U.S.A.

The new study points out the critical need for more information about how the immune system reacts to HCV. It also reinforces the importance of chimpanzee research in this effort. The chimpanzee, the only animal model susceptible to HCV infection, was critical for probing the molecular differences in gene expression in the liver related to infection by the two viruses.

Examination of the adaptive immune system by co-author Christopher M. Walker, Ph.D., of Nationwide Children's Hospital in Columbus, Ohio, found that the T cell response to HAV was unique as well. "We expected the immune response to kill all HAV infected cells in a short time frame, and yet we could detect the genome of the virus in the liver for up to one year, long after symptoms of the disease were resolved," Lanford explained.

"Hepatitis viruses have co-evolved with humans over a very long period of time and they are good at evading the immune system, but nobody understands how hepatitis C becomes a chronic infection," said co-author Stanley M. Lemon, M.D., of UNC.

"The surprising and exciting results of this research program further highlight the critical value of the chimpanzee model in research on hepatitis," said John L. VandeBerg, Ph.D., Texas Biomed's chief scientific officer and SNPRC director

Others on the study included Deborah Chavez, M.S., and Bernadette Guerra, B.S., of Texas Biomed; Kathleen Brasky, D.V.M, of SNPRC; Zongdi Feng, Ph.D., and Daisuke Yamane, D.V.M, Ph.D., of UNC; Yan Zhou, Ph.D., Nationwide Children's Hospital; and Alan S. Perelson, Ph.D., of the Los Alamos National Laboratory.


Story Source:

The above story is based on materials provided by Southwest Foundation for Biomedical Research. Note: Materials may be edited for content and length.


Journal Reference:

  1. Robert E. Lanford, Zongdi Feng, Deborah Chavez, Bernadette Guerra, Kathleen M. Brasky, Yan Zhou, Daisuke Yamane, Alan S. Perelson, Christopher M. Walker, and Stanley M. Lemon. Acute hepatitis A virus infection is associated with a limited type I interferon response and persistence of intrahepatic viral RNA. PNAS, June 20, 2011 DOI: 10.1073/pnas.1101939108

Cite This Page:

Southwest Foundation for Biomedical Research. "How the immune system responds to hepatitis A virus." ScienceDaily. ScienceDaily, 21 June 2011. <www.sciencedaily.com/releases/2011/06/110620161302.htm>.
Southwest Foundation for Biomedical Research. (2011, June 21). How the immune system responds to hepatitis A virus. ScienceDaily. Retrieved October 24, 2014 from www.sciencedaily.com/releases/2011/06/110620161302.htm
Southwest Foundation for Biomedical Research. "How the immune system responds to hepatitis A virus." ScienceDaily. www.sciencedaily.com/releases/2011/06/110620161302.htm (accessed October 24, 2014).

Share This



More Health & Medicine News

Friday, October 24, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

IKEA Desk Converts From Standing to Sitting With One Button

IKEA Desk Converts From Standing to Sitting With One Button

Buzz60 (Oct. 24, 2014) IKEA is out with a new convertible desk that can convert from a sitting desk to a standing one with just the push of a button. Jen Markham explains. Video provided by Buzz60
Powered by NewsLook.com
Ebola Protective Suits Being Made in China

Ebola Protective Suits Being Made in China

AFP (Oct. 24, 2014) A factory in China is busy making Ebola protective suits for healthcare workers and others fighting the spread of the virus. Duration: 00:38 Video provided by AFP
Powered by NewsLook.com
WHO: Millions of Ebola Vaccine Doses by 2015

WHO: Millions of Ebola Vaccine Doses by 2015

AP (Oct. 24, 2014) The World Health Organization said on Friday that millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines would start being tested in March. (Oct. 24) Video provided by AP
Powered by NewsLook.com
Doctor in NYC Quarantined With Ebola

Doctor in NYC Quarantined With Ebola

AP (Oct. 24, 2014) An emergency room doctor who recently returned to the city after treating Ebola patients in West Africa has tested positive for the virus. He's quarantined in a hospital. (Oct. 24) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins